Zhang C - Search Results

1

Neoadjuvant Therapy for Duodenal and Ampullary Adenocarcinoma: A Systematic Review.

Zhang C, Lizalek JM, Dougherty C, Westmark DM, Klute KA, Reames BN. Zhang C, et al. Ann Surg Oncol. 2024 Feb;31(2):792-803. doi: 10.1245/s10434-023-14531-y. Epub 2023 Nov 11. Ann Surg Oncol. 2024. PMID: 37952021 Review.

2

Investigating the utility of extended mutation analysis in gastrointestinal peritoneal metastasis.

Foster JM, Patel A, Zhang C, Shostrom V, Brown K, Cushman-Vokoun AM. Foster JM, et al. Among authors: zhang c. J Surg Oncol. 2020 Nov;122(6):1106-1113. doi: 10.1002/jso.26114. Epub 2020 Jul 13. J Surg Oncol. 2020. PMID: 32662065

3

Exploring the prognostic and therapeutic utility of expanded mutation profiling in appendix peritoneal metastasis managed with CRS/HIPEC.

Zhang C, Plambeck BD, Craig ME, Tu A, Mikus RJ, Shostrom V, McDermott SP, Igbinigie I, Brown K, Cushman-Vokoun A, Foster JM. Zhang C, et al. J Surg Oncol. 2021 Jun;123(7):1599-1609. doi: 10.1002/jso.26439. Epub 2021 Mar 5. J Surg Oncol. 2021. PMID: 33667317

4

Regional therapy trials in peritoneal metastases: The path to standardization of care: Introduction.

Foster JM, Alexander HR, Zhang C. Foster JM, et al. Among authors: zhang c. J Surg Oncol. 2022 Jan;125(1):55-56. doi: 10.1002/jso.26750. Epub 2021 Nov 11. J Surg Oncol. 2022. PMID: 34762306 No abstract available.

5

Regional therapy trials in peritoneal metastases: The path to standardization-Colorectal cancer.

Foster JM, Alexander HR, Zhang C. Foster JM, et al. Among authors: zhang c. J Surg Oncol. 2022 Jan;125(1):57-63. doi: 10.1002/jso.26740. J Surg Oncol. 2022. PMID: 34897714 No abstract available.

6

An evaluation of adjuvant chemotherapy following neoadjuvant chemotherapy and resection for borderline resectable and locally advanced pancreatic cancer.

Zhang C, Wu R, Smith LM, Baine M, Lin C, Reames BN. Zhang C, et al. Am J Surg. 2022 Jul;224(1 Pt A):51-57. doi: 10.1016/j.amjsurg.2021.12.018. Epub 2021 Dec 28. Am J Surg. 2022. PMID: 34973686

7

Cytoreductive Surgery with HIPEC is a Safe and Effective Palliative Option in Chemorefractory Symptomatic Peritoneal Metastasis.

Zhang C, Patel A, Hegeholz D, Brown K, Shostrom V, Pottebaum M, Foster JM. Zhang C, et al. Ann Surg Oncol. 2022 May;29(5):3337-3346. doi: 10.1245/s10434-022-11323-8. Epub 2022 Feb 24. Ann Surg Oncol. 2022. PMID: 35211861

8

ASO Author Reflections: Palliative Management of Peritoneal Metastasis Exploring the Risks and Benefits of CRS/HIPEC, a Distinctly Different Context Than Early CRS/HIPEC Intervention With 'Curative Intent'.

Foster JM, Zhang C. Foster JM, et al. Among authors: zhang c. Ann Surg Oncol. 2022 May;29(5):3347-3348. doi: 10.1245/s10434-022-11377-8. Epub 2022 Feb 25. Ann Surg Oncol. 2022. PMID: 35217972 No abstract available.

9

[No title available]

[No authors listed] [No authors listed] PMID: 35226217

10

Geographic variation in attitudes regarding management of locally advanced pancreatic cancer.

McNeil LR, Blair AB, Krell RW, Zhang C, Ejaz A, Groot VP, Gemenetzis G, Padussis JC, Falconi M, Wolfgang CL, Weiss MJ, Are C, He J, Reames BN. McNeil LR, et al. Among authors: zhang c. Surg Open Sci. 2022 Aug 6;10:97-105. doi: 10.1016/j.sopen.2022.07.007. eCollection 2022 Oct. Surg Open Sci. 2022. PMID: 36062077 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

74,418 results

Search Page

Filters